Status:
COMPLETED
Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction
Lead Sponsor:
Bayer
Conditions:
Myocardial Infarction
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the dose of drug which is most effective in the delineation of dead heart muscle.
Detailed Description
This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc.is the sponsor of the trial.
Eligibility Criteria
Inclusion
- At least 8 weeks post-documented myocardial infarction (heart attack)
Exclusion
- History of radiation therapy to the chest
- Clinically unstable
- Any contraindication for MRI
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
73 Patients enrolled
Trial Details
Trial ID
NCT00310544
Start Date
March 1 2006
End Date
September 1 2006
Last Update
December 15 2014
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
San Diego, California, United States, 92103
2
Winston-Salem, North Carolina, United States, 27103
3
Tulsa, Oklahoma, United States, 74133
4
Portland, Oregon, United States, 97239